Trusted Press Release Distribution   Join | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Credence Research
www.credenceresearch.com/
Chris Smith
sales@credenceresearch.com
18003618290
105 N 1st ST #429, SAN JOSE,, CA 95103, United States
SANJOSE

Bookmark and Share
Cardiac Markers Market Expected To Reach US$ 5,079.5 Mn By 2026
Cardiac Markers Market Expected To Reach US$ 5,079.5 Mn By 2026

BriefingWire.com, 12/05/2018 - Cardiac markers market was valued at US$ 2,515.8 Mn in 2017 and expected to reach US$ 5,079.5 Mn by 2026, expanding at a CAGR of 8.0% from 2018 to 2026.

Browse the full report Cardiac Markers Market 2018 – 2026 report at  www.credenceresearch.com/report/cardiac-markers-market

Market Insights

Cardiovascular diseases (CVDs) are considered as among the leading causes of death worldwide, where it is estimated that 30% of the global deaths are caused by CVDs. The first cardiac marker diagnostics were introduced in the early 1950s and 1960s where creatine kinase, lactate dehydrogenase or aspartate aminotransferase activities were analyzed to diagnose acute myocardial infraction. However, their low specificity and sensitivity were a major challenge for their adoption in the market. The 1980s market significant leap in the field of cardiac markers, with the introduction of the first monoclonal antibodies. Since then, novel cardiac markers are being introduced in the market.

Download Sample research report with TOC and Figures @  www.credenceresearch.com/sample-request/59447

Enzymatic assays and myoglobin assays have been eventually replaced by cardiac troponin I & T. Furthermore, their high sensitivity versions are becoming the need of the hour in acute myocardial infraction diagnostics. Simultaneously, markers for diagnosis of heart failure are also being adopted in routine use in several clinical laboratories. In the recent years, more emphasis is being put on the development of cardiac markers that can be used for prevention and risk assessment of cardiovascular diseases.

The global cardiac markers market is expected to witness steady growth during the forecast period. Rapidly changing lifestyle patterns, widespread incorporation of unhealthy dietary habits, and increasing prevalence of cardiovascular diseases are the key factors driving the growth of cardiac markers market. Furthermore, proliferation of healthcare infrastructure in the Asia Pacific region, along with growing emphasis of risk assessment of cardiac events will open new growth opportunities for the existing players and new market entrants. At present, cardiac troponin tests are considered as the gold standard biomarker for detection of myocardial infraction. The new generation of the high-sensitivity cardiac troponin I assays are also helpful in determining long-term risk assessment of various patient groups that includes patients with stable coronary artery disease and heart failure.

Do inquiry before purchase the Industry Research Report @  www.credenceresearch.com/inquiry-before-buying/59447

Based on the competitive landscape, the global cardiac markers market is characterized by presence of multitude of market players. Some of such players specialize in instruments segment, whereas a majority of players are engaged in manufacturing and marketing of reagents, kits and assays. Among the several market players, Roche Diagnostics, Abbott Laboratories, Siemens AG and Quest Diagnostics are the key companies operating in this space. Other prominent market players include, Danaher Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, LSI Medience Corporation, bioMerieux SA, Ortho Clinical Diagnostics, Randox Laboratories Ltd., Tosoh Bioscience and others.

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2013 Proserve Technology, Inc.